Chester County News and Community Website
MALVERN, PA — CubeSmart (NYSE: CUBE) will release its financial results for the first quarter ended March 31, 2026, after market close on Thursday, April 30, followed by a conference …
CubeSmart to Report First-Quarter 2026 Results April 30 Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) recently reported its full-year 2025 financial results and outlined progress across its QTORIN drug development pipeline, including plans to submit a new …
Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline Read More
MALVERN, PA — Neuronetics, Inc. (Nasdaq: STIM) reported higher fourth-quarter and full-year 2025 revenue, narrowed its losses, posted positive operating cash flow in the fourth quarter, and said Dan Reuvers …
Neuronetics Reports Higher Revenue, Narrows Loss, Sets 2026 Outlook Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) reported its 2025 financial results and said it advanced late-stage clinical development of its investigational drug buntanetap, including launching a Phase 3 …
Annovis Reports 2025 Results, Advances Buntanetap Trials Read More
WAYNE, PA — Trinseo (NYSE: TSE) reported a fourth-quarter 2025 net loss of $251 million and a full-year net loss of $546 million, driven by lower sales volumes, pricing pressure, …
Trinseo Reports 2025 Loss as Sales Decline and Restructuring Costs Rise Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported financial results for the fourth quarter and full year ended December 31, 2025, citing growth in sales of its dermatology …
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth Read More
MALVERN, PA — TELA Bio Inc. (NASDAQ: TELA) said it will report financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 24, 2026.
TELA Bio to Report Fourth Quarter and Full-Year 2025 Results March 24 Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will host a conference call and live webcast Wednesday to discuss its financial results for the fourth quarter …
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results Read More
EXTON, PA — Omega Flex, Inc. (NASDAQ: OFLX) reported net sales of $98,296,000 for 2025, down from $101,681,000 in 2024, as lower unit volumes weighed on performance.
Omega Flex Reports Lower Sales and Net Income for 2025 Read More
MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) reported fourth quarter and full-year 2025 financial results and provided updates on its clinical pipeline, including completion of enrollment for a Phase 3 …
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline Read More